Study Finds Pembrolizumab Delivers Clinical Benefit in Selected Histotypes of Rare Sarcoma
September 24th 2020The results from a cohort of patients with rare sarcomas in the phase 2 study, presented by professor Jean-Yves Blay, MD, investigated the efficacy and safety of single agent pembrolizumab in rare cancers.
Results of Phase 3 Study Find New First-Line Treatment Option for Metastatic Kidney Cancer
September 23rd 2020The CheckMate 9ER trial took 2 drugs used as monotherapies in the second line of therapy, nivolumab and cabozantinib, and combined them for use as a first-line treatment against standard of care, sunitinib.
Trial Finds Breast Cancer Drug Set to Transform Prostate Cancer Treatment
September 22nd 2020Trial shows that olaparib, a poly ADP ribose polymerase inhibitor that is the first cancer drug to target an inherited genetic fault, can be used successfully to treat prostate cancers with a weakness in the ability to repair damaged DNA.
Provider Collaboration Prevents Medication Errors in the Oncology Setting
October 22nd 2019At the ESMO Congress 2019, Sara Tolaney, MD, MPH, of Dana-Farber Cancer Institute, spoke about how a collaborative program between pharmacists and oncology providers at her institution helps prevent medication errors.
Precision Medicine in Oncology: More Strategies for Identifying Patients Needed
September 30th 2019At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen, discussed the increasing value of precision medicine in oncology and what will be needed to facilitate the use of precision medicine as more agents become available.
Positive Larotrectinib Data for TRK Fusion Cancer Presented at ESMO
September 29th 2019At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, professor of oncology at the University of Copenhagen, discussed the newly-released clinical data highlighting new overall survival and progression-free survival results for larotrectinib (Vitrakvi, Bayer) in tropomyosin receptor kinase (TRK) fusion cancer.
Two New Studies Report Significant Benefit With CDK4/6 Inhibitors in Advanced Breast Cancer
September 29th 2019Treatment with a CDK4/6 inhibitor plus fulvestrant found to improve overall survival in women with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer.
Pharmacist/Nurse Led Clinic Eases Care for Melanoma
September 29th 2019A pharmacist and nurse led non-medical prescribing clinic that was focused on side effect management and survivorship support for patients with melanoma helped to improve common every-day pressure seen in a medical day unit and improved overall patient experience.